Literature DB >> 15770388

Endovascular therapy of renal artery stenosis: where do we stand today?

Michael Uder1, Ulrich Humke.   

Abstract

Angioplasty and stent therapy for stenoses of the renal artery have long been part of the everyday life of interventional radiologists. Newer studies, however, challenge the clinical significance of the method. A decisive advantage of endovascular techniques for the treatment of arterial hypertension as opposed to therapy with modern antihypertensives could not be proven in individual randomized studies, even though blood pressure control was observed to be facilitated by PTA (percutaneous transluminal angioplasty). Renal function often did not show any sustainable improvement following elimination of the renal artery stenosis. However, progression of kidney insufficiency could be slowed down. There is still no general justification from the existing data for the treatment of incidental stenoses. Many questions remain open regarding the technique. Whereas fibromuscular dysplasia can be treated by balloon angioplasty as a general rule, a metallic endoprosthesis must often be used for atherosclerotic stenoses. The outstanding morphologic results of stent therapy in the short and medium term course are often simply used to justify primary stent implantation in ostial stenoses.

Entities:  

Mesh:

Year:  2005        PMID: 15770388     DOI: 10.1007/s00270-004-0083-8

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  2 in total

1.  Recovery of renal function after delayed percutaneous dilation of a subtotal in-stent restenosis of the renal artery in a left solitary kidney.

Authors:  Alexandra R Zankl; Thomas J Dengler; Martin Andrassy; Hans C Volz; Hugo A Katus; Martin Zeier
Journal:  NDT Plus       Date:  2009-03-31

2.  Percutaneous renal artery stent implantation in the treatment of atherosclerotic renal artery stenosis.

Authors:  Youbin Hu; Yongguang Zhang; Hua Wang; Yong Yin; Chunhua Cao; Jing Luo; Yunfei Wang
Journal:  Exp Ther Med       Date:  2018-07-13       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.